Skip to main content

11.09.2024 | RESEARCH ARTICLE

Using machine learning methods to investigate the impact of age on the causes of death in patients with early intrahepatic cholangiocarcinoma who underwent surgery

verfasst von: Shiqin Song, Shixiong Song, Huarong Zhao, Shike Huang, Xinghua Xiao, Xiaobo Lv, Yuehong Deng, Yiyin Tao, Yanlin Liu, Ke Su, Shansha Cheng

Erschienen in: Clinical and Translational Oncology

Einloggen, um Zugang zu erhalten

Abstract

Background

The impact of age on the causes of death (CODs) in patients with early-stage intrahepatic cholangiocarcinoma (ICC) who had undergone surgery was analyzed in this study.

Methods

A total of 1555 patients (885 in the older group and 670 in the younger group) were included in this study. Before and after applying inverse probability of treatment weighting (IPTW), the different CODs in the 2 groups were further investigated. Additionally, 7 different machine learning models were used as predictive tools to identify key variables, aiming to evaluate the therapeutic outcome in early ICC patients undergoing surgery.

Results

Before (5.92 vs. 4.08 years, P < 0.001) and after (6.00 vs. 4.08 years, P < 0.001) IPTW, the younger group consistently showed longer overall survival (OS) compared with the older group. Before IPTW, there were no significant differences in cholangiocarcinoma-related deaths (CRDs, P = 0.7) and secondary malignant neoplasms (SMNs, P = 0.78) between the 2 groups. However, the younger group had a lower cumulative incidence of cardiovascular disease (CVD, P = 0.006) and other causes (P < 0.001) compared with the older group. After IPTW, there were no differences between the 2 groups in CRDs (P = 0.2), SMNs (P = 0.7), and CVD (P = 0.1). However, the younger group had a lower cumulative incidence of other CODs compared with the older group (P < 0.001). The random forest (RF) model showed the highest C-index of 0.703. Time-dependent variable importance bar plots showed that age was the most important factor affecting the 2-, 4-, and 6-year survival, followed by stage and size.

Conclusions

Our study confirmed that younger patients have longer OS compared with older patients. Further analysis of the CODs indicated that older patients are more likely to die from CVDs. The RF model demonstrated the best predictive performance and identified age as the most important factor affecting OS in early ICC patients undergoing surgery.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat El-Diwany R, Pawlik TM, Ejaz A. Intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am. 2019;28(4):587–99.CrossRefPubMed El-Diwany R, Pawlik TM, Ejaz A. Intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am. 2019;28(4):587–99.CrossRefPubMed
2.
Zurück zum Zitat Lee AJ, Chun YS. Intrahepatic cholangiocarcinoma: the AJCC/UICC updates. Chine Clin Oncol. 2018;7(5):52.CrossRef Lee AJ, Chun YS. Intrahepatic cholangiocarcinoma: the AJCC/UICC updates. Chine Clin Oncol. 2018;7(5):52.CrossRef
3.
Zurück zum Zitat Cillo U, Fondevila C, Donadon M, Gringeri E, Mocchegiani F, Schlitt HJ, et al. Surgery for cholangiocarcinoma. Liver Int: Off J Int Assoc Study Liver. 2019;39(Suppl 1):143–55.CrossRef Cillo U, Fondevila C, Donadon M, Gringeri E, Mocchegiani F, Schlitt HJ, et al. Surgery for cholangiocarcinoma. Liver Int: Off J Int Assoc Study Liver. 2019;39(Suppl 1):143–55.CrossRef
4.
Zurück zum Zitat Mazzaferro V, Gorgen A, Roayaie S, Droz Dit Busset M, Sapisochin G. Liver resection and transplantation for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72(2):364–77.CrossRefPubMed Mazzaferro V, Gorgen A, Roayaie S, Droz Dit Busset M, Sapisochin G. Liver resection and transplantation for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72(2):364–77.CrossRefPubMed
5.
Zurück zum Zitat Antwi SO, Mousa OY, Patel T. Racial, ethnic, and age disparities in incidence and survival of intrahepatic cholangiocarcinoma in the United States; 1995–2014. Ann Hepatol. 2018;17(4):604–14.CrossRefPubMed Antwi SO, Mousa OY, Patel T. Racial, ethnic, and age disparities in incidence and survival of intrahepatic cholangiocarcinoma in the United States; 1995–2014. Ann Hepatol. 2018;17(4):604–14.CrossRefPubMed
6.
Zurück zum Zitat Wiazzane N, Chauffert B, Ghiringhelli F. Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma. Clin Res Hepatol Gastroenterol. 2013;37(6):614–8.CrossRefPubMed Wiazzane N, Chauffert B, Ghiringhelli F. Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma. Clin Res Hepatol Gastroenterol. 2013;37(6):614–8.CrossRefPubMed
7.
Zurück zum Zitat Kim JH, Cheon YK, Lee TY, Lee SH, Chung H. Effect of age on the prognosis of intrahepatic cholangiocarcinoma. Korean J Intern Med. 2023;38(1):39–47.CrossRefPubMed Kim JH, Cheon YK, Lee TY, Lee SH, Chung H. Effect of age on the prognosis of intrahepatic cholangiocarcinoma. Korean J Intern Med. 2023;38(1):39–47.CrossRefPubMed
8.
Zurück zum Zitat Poruk KE, Pawlik TM, Weiss MJ. Perioperative management of hilar cholangiocarcinoma. J Gastrointestinal Surg: Off J Soc Surg Aliment Tract. 2015;19(10):1889–99.CrossRef Poruk KE, Pawlik TM, Weiss MJ. Perioperative management of hilar cholangiocarcinoma. J Gastrointestinal Surg: Off J Soc Surg Aliment Tract. 2015;19(10):1889–99.CrossRef
9.
Zurück zum Zitat Guda BB, Komisarenko II, Ostafiichuk MV, Tronko MD. Familial non-medullary thyroid carcinoma. Exp Oncol. 2023;45(1):70–8.CrossRefPubMed Guda BB, Komisarenko II, Ostafiichuk MV, Tronko MD. Familial non-medullary thyroid carcinoma. Exp Oncol. 2023;45(1):70–8.CrossRefPubMed
10.
Zurück zum Zitat Reimers LL, Anderson WF, Rosenberg PS, Henson DE, Castle PE. Etiologic heterogeneity for cervical carcinoma by histopathologic type, using comparative age-period-cohort models. Cancer Epidemiol, Biomark Prev: Publ Am Assoc Cancer Res, Cosponsored Am Soc Prev Oncol. 2009;18(3):792–800.CrossRef Reimers LL, Anderson WF, Rosenberg PS, Henson DE, Castle PE. Etiologic heterogeneity for cervical carcinoma by histopathologic type, using comparative age-period-cohort models. Cancer Epidemiol, Biomark Prev: Publ Am Assoc Cancer Res, Cosponsored Am Soc Prev Oncol. 2009;18(3):792–800.CrossRef
11.
Zurück zum Zitat Greener JG, Kandathil SM, Moffat L, Jones DT. A guide to machine learning for biologists. Nat Rev Mol Cell Biol. 2022;23(1):40–55.CrossRefPubMed Greener JG, Kandathil SM, Moffat L, Jones DT. A guide to machine learning for biologists. Nat Rev Mol Cell Biol. 2022;23(1):40–55.CrossRefPubMed
12.
Zurück zum Zitat Lee YW, Choi JW, Shin EH. Machine learning model for predicting malaria using clinical information. Comput Biol Med. 2021;129: 104151.CrossRefPubMed Lee YW, Choi JW, Shin EH. Machine learning model for predicting malaria using clinical information. Comput Biol Med. 2021;129: 104151.CrossRefPubMed
13.
Zurück zum Zitat Wingert T, Lee C, Cannesson M. Machine learning, deep learning, and closed loop devices-anesthesia delivery. Anesthesiol Clin. 2021;39(3):565–81.CrossRefPubMedPubMedCentral Wingert T, Lee C, Cannesson M. Machine learning, deep learning, and closed loop devices-anesthesia delivery. Anesthesiol Clin. 2021;39(3):565–81.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Linthicum KP, Schafer KM, Ribeiro JD. Machine learning in suicide science: applications and ethics. Behav Sci Law. 2019;37(3):214–22.CrossRefPubMed Linthicum KP, Schafer KM, Ribeiro JD. Machine learning in suicide science: applications and ethics. Behav Sci Law. 2019;37(3):214–22.CrossRefPubMed
15.
Zurück zum Zitat Lo Vercio L, Amador K, Bannister JJ, Crites S, Gutierrez A, MacDonald ME, et al. Supervised machine learning tools: a tutorial for clinicians. J Neural Eng. 2020;17(6):062001.CrossRef Lo Vercio L, Amador K, Bannister JJ, Crites S, Gutierrez A, MacDonald ME, et al. Supervised machine learning tools: a tutorial for clinicians. J Neural Eng. 2020;17(6):062001.CrossRef
16.
Zurück zum Zitat Yang Z, Shi G. Survival outcomes of combined hepatocellular-cholangiocarcinoma compared with intrahepatic cholangiocarcinoma: A SEER population-based cohort study. Cancer Med. 2022;11(3):692–704.CrossRefPubMed Yang Z, Shi G. Survival outcomes of combined hepatocellular-cholangiocarcinoma compared with intrahepatic cholangiocarcinoma: A SEER population-based cohort study. Cancer Med. 2022;11(3):692–704.CrossRefPubMed
17.
Zurück zum Zitat Li P, Song L. A novel prognostic nomogram for patients with surgically resected perihilar cholangiocarcinoma: a SEER-based study. Ann Trans Med. 2021;9(1):54.CrossRef Li P, Song L. A novel prognostic nomogram for patients with surgically resected perihilar cholangiocarcinoma: a SEER-based study. Ann Trans Med. 2021;9(1):54.CrossRef
18.
Zurück zum Zitat Anderson WF, Pfeiffer RM, Dores GM, Sherman ME. Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol, Biomark Prev: Publ Am Assoc Cancer Res, Cosponsored Am Soc Prev Oncol. 2006;15(10):1899–905.CrossRef Anderson WF, Pfeiffer RM, Dores GM, Sherman ME. Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol, Biomark Prev: Publ Am Assoc Cancer Res, Cosponsored Am Soc Prev Oncol. 2006;15(10):1899–905.CrossRef
19.
Zurück zum Zitat Cabanillas ME, Zafereo M, Gunn GB, Ferrarotto R. Anaplastic thyroid carcinoma: treatment in the age of molecular targeted therapy. J Oncol Pract. 2016;12(6):511–8.CrossRefPubMed Cabanillas ME, Zafereo M, Gunn GB, Ferrarotto R. Anaplastic thyroid carcinoma: treatment in the age of molecular targeted therapy. J Oncol Pract. 2016;12(6):511–8.CrossRefPubMed
20.
Zurück zum Zitat Morand GB, Anderegg N, Vital D, Ikenberg K, Huber GF, Soyka MB, et al. Outcome by treatment modality in sinonasal undifferentiated carcinoma (SNUC): a case-series, systematic review and meta-analysis. Oral Oncol. 2017;75:28–34.CrossRefPubMed Morand GB, Anderegg N, Vital D, Ikenberg K, Huber GF, Soyka MB, et al. Outcome by treatment modality in sinonasal undifferentiated carcinoma (SNUC): a case-series, systematic review and meta-analysis. Oral Oncol. 2017;75:28–34.CrossRefPubMed
21.
22.
Zurück zum Zitat Andrus MR, Loyed JV. Use of beta-adrenoceptor antagonists in older patients with chronic obstructive pulmonary disease and cardiovascular co-morbidity: safety issues. Drugs Aging. 2008;25(2):131–44.CrossRefPubMed Andrus MR, Loyed JV. Use of beta-adrenoceptor antagonists in older patients with chronic obstructive pulmonary disease and cardiovascular co-morbidity: safety issues. Drugs Aging. 2008;25(2):131–44.CrossRefPubMed
23.
Zurück zum Zitat Forman DE, Alexander K, Brindis RG, Curtis AB, Maurer M, Rich MW, et al. Improved cardiovascular disease outcomes in older adults. F1000Research. 2016;5(4):122–30. Forman DE, Alexander K, Brindis RG, Curtis AB, Maurer M, Rich MW, et al. Improved cardiovascular disease outcomes in older adults. F1000Research. 2016;5(4):122–30.
24.
Zurück zum Zitat Su K, Wang F, Li X, Chi H, Zhang J, He K, et al. Effect of external beam radiation therapy versus transcatheter arterial chemoembolization for non-diffuse hepatocellular carcinoma (≥ 5 cm): a multicenter experience over a ten-year period. Front Immunol. 2023;14:1265959.CrossRefPubMedPubMedCentral Su K, Wang F, Li X, Chi H, Zhang J, He K, et al. Effect of external beam radiation therapy versus transcatheter arterial chemoembolization for non-diffuse hepatocellular carcinoma (≥ 5 cm): a multicenter experience over a ten-year period. Front Immunol. 2023;14:1265959.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Su K, Guo L, Ma W, Wang J, Xie Y, Rao M, et al. PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study. Front Immunol. 2022;13: 972503.CrossRefPubMedPubMedCentral Su K, Guo L, Ma W, Wang J, Xie Y, Rao M, et al. PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study. Front Immunol. 2022;13: 972503.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Hébert-Losier K, Wessman C, Alricsson M, Svantesson U. Updated reliability and normative values for the standing heel-rise test in healthy adults. Physiotherapy. 2017;103(4):446–52.CrossRefPubMed Hébert-Losier K, Wessman C, Alricsson M, Svantesson U. Updated reliability and normative values for the standing heel-rise test in healthy adults. Physiotherapy. 2017;103(4):446–52.CrossRefPubMed
27.
Zurück zum Zitat Hamaoka M, Kozaka K, Matsui O, Komori T, Matsubara T, Yoneda N, et al. Early detection of intrahepatic cholangiocarcinoma. Jpn J Radiol. 2019;37(10):669–84.CrossRefPubMed Hamaoka M, Kozaka K, Matsui O, Komori T, Matsubara T, Yoneda N, et al. Early detection of intrahepatic cholangiocarcinoma. Jpn J Radiol. 2019;37(10):669–84.CrossRefPubMed
28.
Zurück zum Zitat Kong J, Cao Y, Chai J, Liu X, Lin C, Wang J, et al. Effect of tumor size on long-term survival after resection for solitary intrahepatic cholangiocarcinoma. Front Oncol. 2020;10: 559911.CrossRefPubMed Kong J, Cao Y, Chai J, Liu X, Lin C, Wang J, et al. Effect of tumor size on long-term survival after resection for solitary intrahepatic cholangiocarcinoma. Front Oncol. 2020;10: 559911.CrossRefPubMed
29.
Zurück zum Zitat Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, et al. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2016;34(5):460–8.CrossRef Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, et al. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2016;34(5):460–8.CrossRef
30.
Zurück zum Zitat Thapelo TS, Mpoeleng D, Hillhouse G. Informed random forest to model associations of epidemiological priors, government policies, and public mobility. MDM Policy Pract. 2023;8(2):23814683231218716.CrossRefPubMedPubMedCentral Thapelo TS, Mpoeleng D, Hillhouse G. Informed random forest to model associations of epidemiological priors, government policies, and public mobility. MDM Policy Pract. 2023;8(2):23814683231218716.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Shi G, Liu G, Gao Q, Zhang S, Wang Q, Wu L, et al. A random forest algorithm-based prediction model for moderate to severe acute postoperative pain after orthopedic surgery under general anesthesia. BMC Anesthesiol. 2023;23(1):361.CrossRefPubMedPubMedCentral Shi G, Liu G, Gao Q, Zhang S, Wang Q, Wu L, et al. A random forest algorithm-based prediction model for moderate to severe acute postoperative pain after orthopedic surgery under general anesthesia. BMC Anesthesiol. 2023;23(1):361.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Dai P, Chang W, Xin Z, Cheng H, Ouyang W, Luo A. Retrospective study on the influencing factors and prediction of hospitalization expenses for chronic renal failure in china based on random forest and LASSO regression. Front Public Health. 2021;9: 678276.CrossRefPubMedPubMedCentral Dai P, Chang W, Xin Z, Cheng H, Ouyang W, Luo A. Retrospective study on the influencing factors and prediction of hospitalization expenses for chronic renal failure in china based on random forest and LASSO regression. Front Public Health. 2021;9: 678276.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Shen Z, Zhang S, Jiao Y, Shi Y, Zhang H, Wang F, et al. LASSO model better predicted the prognosis of DLBCL than Random forest model: a retrospective multicenter analysis of HHLWG. J Oncol. 2022;2022:1618272.CrossRefPubMedPubMedCentral Shen Z, Zhang S, Jiao Y, Shi Y, Zhang H, Wang F, et al. LASSO model better predicted the prognosis of DLBCL than Random forest model: a retrospective multicenter analysis of HHLWG. J Oncol. 2022;2022:1618272.CrossRefPubMedPubMedCentral
Metadaten
Titel
Using machine learning methods to investigate the impact of age on the causes of death in patients with early intrahepatic cholangiocarcinoma who underwent surgery
verfasst von
Shiqin Song
Shixiong Song
Huarong Zhao
Shike Huang
Xinghua Xiao
Xiaobo Lv
Yuehong Deng
Yiyin Tao
Yanlin Liu
Ke Su
Shansha Cheng
Publikationsdatum
11.09.2024
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-024-03716-w

Neu im Fachgebiet Onkologie

Studie zur HIFU bei Prostatakrebs lässt viele Fragen offen

Führt eine HIFU-Ablation beim Prostatakarzinom im Vergleich mit einer radikalen Prostatektomie zu ähnlichen onkologischen, aber besseren funktionalen Ergebnissen? Interimsdaten der französischen HIFI-Studie sind uneindeutig. In einem Kommentar zur Studie werden zumindest drei allgemeine Erkenntnisse herausgearbeitet.

Bei Achalasie auf Candidiasis der Speiseröhre achten!

Bei Achalasie-Betroffenen sollte man immer auch auf Candida-Infektionen achten, warnen Forschende aus Rotterdam. In ihrer Studie ließ die Pilzinfektion das Risiko für ein Ösophaguskarzinom massiv steigen.

Adipositas als negativer Prognosefaktor bei Kindern mit Krebs

Eine kanadische Studie weist darauf hin, dass Übergewicht zum Zeitpunkt der Krebsdiagnose ein unabhängiger Risikofaktor für schlechtere Überlebenschancen bei erkrankten Kindern und Jugendlichen sein könnte. Allerdings sind nicht alle Patientinnen und Patienten gleichermaßen betroffen.


Polypen bei nahen Verwandten – erhöhtes Darmkrebsrisiko

Werden bei erstgradigen Verwandten gutartige Darmpolypen identifiziert, ist das Risiko, selbst an einem Kolorektalkarzinom zu erkranken, deutlich erhöht – vor allem das für eine früh beginnende Erkrankung. Hier könnte sich eine frühe Koloskopie besonders lohnen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.